Abstract:Over the past decade, in vivo gene replacement therapy has significantly advanced, resulting in market approval of numerous therapeutics predominantly relying on adeno‐associated viral vectors (AAV). While viral vectors have undeniably addressed several critical healthcare challenges, their clinical application has unveiled a range of limitations and safety concerns. This review highlights the emerging challenges in the field of gene therapy. At first, we discuss both the role of biological barriers in viral gene therapy with a focus on AAVs, and review current landscape of in vivo human gene therapy. We delineate advantages and disadvantages of AAVs as gene delivery vehicles, mostly from the safety perspective (hepatotoxicity, cardiotoxicity, neurotoxicity, inflammatory responses etc.), and outline the mechanisms of adverse events in response to AAV. Contribution of every aspect of AAV vectors (genomic structure, capsid proteins) and host responses to injected AAV is considered and substantiated by basic, translational and clinical studies. The updated evaluation of recent AAV clinical trials and current medical experience clearly shows the risks of AAVs that sometimes overshadow the hopes for curing a hereditary disease. At last, a set of established and new molecular and nanotechnology tools and approaches are provided as potential solutions for mitigating or eliminating side effects. The increasing number of severe adverse reactions and, sadly deaths, demands decisive actions to resolve the issue of immune responses and extremely high doses of viral vectors used for gene therapy. In response to these challenges, various strategies are under development, including approaches aimed at augmenting characteristics of viral vectors and others focused on creating secure and efficacious non‐viral vectors. This comprehensive review offers an overarching perspective on the present state of gene therapy utilizing both viral and non‐viral vectors.

Immune Responses to Viral Gene Therapy Vectors

Innate Immune Response to Viral Vectors in Gene Therapy

Viral vector‐based gene therapies in the clinic

Clinical and Translational Landscape of Viral Gene Therapies

Viral vector platforms within the gene therapy landscape

Immunogenicity of Recombinant Adeno-Associated Virus (AAV) Vectors for Gene Transfer

The menace of severe adverse events and deaths associated with viral gene therapy and its potential solution

Viral Vectors in Gene Therapy: Where Do We Stand in 2023?

Viral Vector Systems for Gene Therapy: A Comprehensive Literature Review of Progress and Biosafety Challenges

Adenoviral Vector System: A Comprehensive Overview of Constructions, Therapeutic Applications and Host Responses

Adeno‐associated Virus Vectors for Gene Therapy—focusing on Melanoma

Adeno-Associated Virus Engineering and Load Strategy for Tropism Modification, Immune Evasion and Enhanced Transgene Expression

Understanding AAV vector immunogenicity: from particle to patient

Adeno-associated virus vector as a platform for gene therapy delivery

Adenoviral Vectors for Gene Therapy of Hereditary Diseases

Human Immune Responses to Adeno-Associated Virus (AAV) Vectors

Adeno-Associated Virus Vectors-a Target of Cellular and Humoral Immunity-are Expanding Their Reach Toward Hematopoietic Stem Cell Modification and Immunotherapies

Latest Developments in Gene Transfer Technology: Achievements, Perspectives, and Controversies over Therapeutic Applications

A primer to gene therapy: Progress, prospects, and problems

Adeno-associated virus as a delivery vector for gene therapy of human diseases

Non-viral Vectors in Gene Therapy: Recent Development, Challenges, and Prospects